Associate Director, DMPK
Edgewise Therapeutics
Marilyn Mok, Ph.D., is an Associate Director of DMPK at Edgewise Therapeutics. Since joining the company in 2022, Dr. Mok has primarily contributed to the cardiovascular programs. She previously held positions at Gilead Sciences and led the DMPK efforts in multiple oncology and inflammatory research projects. Dr. Mok received her Ph.D. in Pharmaceutical Sciences and Pharmacogenomics from the University of California, San Francisco and also holds a B.S. in Genetics from the University of California, Davis. Her scientific awards include receiving the James R. Gillette award (2017) for the most outstanding paper in the Pharmacokinetics/Drug Transporters category for her Drug Metabolism and Disposition publication, "Interaction of 2,4-Diaminopyrimidine–Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters".